Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...

Texas has reached consecutive College Football Playoff semifinals and posted 25 wins over two years. You have to go all the ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

The Vermont Department of Health recently released data from the state's first registry for the disease Amyotrophic Lateral ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

For men, high levels of physical activity and fitness are associated with reduced risk of amyotrophic lateral sclerosis (ALS).

Thanks to awareness-raising initiatives like the Ice Bucket Challenge, we all have a better appreciation of amyotrophic lateral sclerosis (ALS) and its debilitating effects. The progressive ...

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its primary endpoint of slowing disease progression compared with placebo at week 24.According ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...